7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with celecoxib in 4 studies
| Studies (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Trials (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Recent Studies (post-2010) (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 39 | 15 | 14 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK | 1 |
| Frölich, JC; Gutzki, FM; Marhauer, V; Stichtenoth, DO; Tsikas, D | 1 |
| Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F | 1 |
| Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK | 1 |
4 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and celecoxib
| Article | Year |
|---|---|
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Body Weight; Celecoxib; Creatinine; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Diuretics; Female; Furosemide; Humans; Indomethacin; Kidney; Potassium; Prostaglandins; Pyrazoles; Renin; Sodium; Sulfonamides; Thromboxane B2 | 2005 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2009 |
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Topics: Adult; Arachidonate 5-Lipoxygenase; Biomarkers; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Maximum Tolerated Dose; Prognosis; Prostaglandins; Pyrazoles; Smoking; Sulfonamides; Tandem Mass Spectrometry | 2013 |